Given the growing recognition of the interplay between metabolic dysfunction and neurodegeneration, GLP-1 RAs may offer a novel, dual-acting strategy that not only targets core pathological mechanisms of PD but also addresses systemic comorbidities. The gene discussed is GCG; the disease is Parkinson disease.